| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Reimagining Molecules to Advance Medicine Corporate Presentation – April 2022 | | | | | | | | | | | | | Safe Harbor SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. ("Eton", the "Company," ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Mitchell Kapoor – H. C. Wainwright Justin Walsh – B. Riley Operator Good afternoon. And welcome to the Eton Pharmaceuticals’ First Quarter 2022 Financial Results Conference Call. At this time, all parti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charte ...

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2021 Earnings Conference Call March 16, 2022 7:00 PM ET Company Participants David Krempa - Senior Vice President, Business Development & Investor Relations Sean Brynjelsen - Chief Executive Officer Wilson Troutman – Chief Financial Officer Kevin Guthrie - Executive Vice President-Commercial Activities Conference Call Participants Mitchell Kapoor - H.C. Wainwright Justin Walsh - B. Riley Securities Operator Good evening, and welcome to the Eton Pharmaceuticals Fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------|-----------------------------------------------------| | FOR THE TRANSITION PERIOD FROM ...

| --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Reimagining Molecules to Advance Medicine Corporate Presentation – November 2021 | | | | | | | | | | | | | Safe Harbor SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking statements concerning Eton Pharmaceuticals, Inc. ("Eton", the "Com ...

Eton Pharmaceuticals (NASDAQ:ETON) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relations Sean Brynjelsen – Chief Executive Officer Wilson Troutman – Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon and welcome to the Eton Pharmaceuticals’ Third Quarter 2021 Financial and Operating Results Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its ch ...

Financial Data and Key Metrics Changes - Eton Pharmaceuticals reported revenue of $3.1 million for Q2 2021, which included $2.5 million of licensing revenue from a transaction with Azurity, compared to no material revenue in the prior year period [19] - General and administrative expenses increased to $3.3 million from $2.9 million year-over-year, primarily due to commercialization costs for ALKINDI SPRINKLE [20] - R&D expenses rose to $2.0 million from $1.6 million in the prior year, including a one-time $0.5 million payment for acquiring rights to ZENEO Hydrocortisone [21] - The net loss for Q2 2021 was $2.0 million, a decrease from a net loss of $4.7 million in the prior year, resulting in a loss of $0.08 per share compared to a loss of $0.23 per share previously [21] - Cash and cash equivalents at the end of Q2 2021 stood at $25.8 million, sufficient for product launches and business development opportunities [22] Business Line Data and Key Metrics Changes - The approval of Rezipres, a ready-to-use formulation of ephedrine injection, marks the fourth FDA approval for Eton, with nearly 50% of the nine products in the pipeline now approved [6][18] - ALKINDI SPRINKLE has seen growing sales, with the company planning to expand its field sales force to increase physician engagement [12][18] Market Data and Key Metrics Changes - Eton expects to launch Rezipres at a slight premium to the concentrated ephedrine injection, which sees over 6 million vials sold annually in the U.S. market [7] - The company has received favorable support from payers for ALKINDI, with over 90% of patients being reimbursed for the product [13] Company Strategy and Development Direction - Eton is focused on expanding its orphan drug pipeline and has acquired rights to ZENEO Hydrocortisone, which complements ALKINDI SPRINKLE [8][9] - The company aims to increase in-person meetings with physicians, which have proven to be more effective than virtual meetings, to drive product adoption [11][12] - Eton is optimistic about upcoming product approvals and believes it is well-positioned for strong growth in 2022 and beyond [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook, citing the successful launch of ALKINDI and the upcoming launch of Rezipres [18] - The company acknowledges COVID-related challenges but remains optimistic about continuing to reach prescribing doctors face-to-face [14][25] - Management believes that the current cash position and upcoming product approvals will support growth without the need for external financing [18][22] Other Important Information - The company is preparing for the PDUFA date of November 6th for topiramate, with expectations of no inspection issues during the review [15] - Eton is addressing CRLs (Complete Response Letters) and is working to minimize future occurrences through enhanced oversight and consultation [32][33] Q&A Session Summary Question: Concerns about ALKINDI labeling and FDA involvement - Management acknowledged awareness of the issue and clarified that it was an inadvertent error regarding a Google ad, which has since been corrected [23] Question: Sales modeling for ALKINDI amid Delta variant concerns - Management believes that the population's resistance to the Delta variant will allow continued face-to-face interactions with physicians, indicating a strong growth potential for ALKINDI [24][25] Question: Product revenue breakout and expectations for Rezipres - Management did not provide specific product revenue breakdowns but indicated that ALKINDI will be the primary revenue driver moving forward [27] Question: Competition for ZENEO auto-injector - Management noted that Antares Pharma announced a competing product, but they believe there is enough market space for both products [29][30] Question: Future regulatory milestone payments from Azurity - Management expects the topiramate milestone payment to occur in 2021, with other payments likely in early 2022 [38] Question: Review period for dehydrated alcohol injection application amendment - Management anticipates a three-month review period for the amendment, assuming it is classified as minor [40] Question: Confidence in litigation regarding Cysteine injection - Management expressed strong confidence in their position, citing long-term production of the product and the immorality of opposing claims [42]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _______________________ Commission file number: 001-38738 ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter ...